Toni Stephenson Lymphoma Center Publication Highlights

Name: Toni Stephenson Lymphoma Center Publication Highlights
Keywords: lymphoma, lymphoma research, toni stephenson, toni stephenson lymphoma center publications, lymphoma research publications

Budde, L.E., Sehn, L.H., Matasar, M., Schuster, S.J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L., Cheah, C.Y., Wei, M.C., Yin, S., Li, C.C., Huang, H., Kwan, A., Penuel, E., & Bartlett, N.L. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055-1065. PMID: 35803286.
Mei, M.G., Lee, H.J., Palmer, J.M., Chen, R., Tsai, N.C., Chen, L., McBride, K., Smith, D.L., Melgar, I., Song, J.Y., Bonjoc, K.J., Armenian, S., Nwangwu, M., Lee, P.P., Zain, J., Nikolaenko, L., Popplewell, L., Nademanee, A., Chaudhry, A., Rosen, S., Kwak, L., Forman, S.J., & Herrera, A.F. Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE. Blood. 2022;139(25):3605-3616. PMID: 35316328; PMCID: PMC9227101.
Liu, T., Lam, V., Thieme, E., Sun, D., Wang, X., Xu, F., Wang, L., Danilova, O.V., Xia, Z., Tyner, J.W., Kurtz, S.E., & Danilov, A.V. Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent Manner. Clin Cancer Res. 2021;27(17):4910-4922. PMID: 34233959; PMCID: PMC8416922.
Querfeld, C., Thompson, J.A., Taylor, M.H., DeSimone, J.A., Zain, J.M., Shustov, A.R., Johns, C., McCann, S., Lin, G.H.Y., Petrova, P.S., Uger, R.A., Molloy, N., Shou, Y., & Akilov, O.E. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. Lancet Haematol. 2021 Nov;8(11):e808-e817. PMID: 34627593.
Herrera, A.F., Chen, L., Nieto, Y., Holmberg, L., Johnston, P., Mei, M., Popplewell, L., Armenian, S., Cao, T., Farol, F., Sahebi, F., Spielberger, R., Chen, R., Nademanee, A., Puverel, S., Nwangwu, M., Lee, P., Song, J., Skarbnik, A., Kennedy, N., Peters, L., Rosen, S.T., Kwak, L.W., Forman, S.J., & Feldman, T. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2022 (In press).
Budde, L.E., Assouline, S., Sehn, L.H., Schuster, S.J., Yoon, S.S., Yoon, D.H., Matasar, M.J., Bosch, F., Kim, W.S., Nastoupil, L.J., Flinn, I.W., Shadman, M., Diefenbach, C., O'Hear, C., Huang, H., Kwan, A., Li, C.C., Piccione, E.C., Wei, M.C., Yin, S., & Bartlett, N.L. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. J Clin Oncol. 2022;40(5):481-491. PMID: 34914545; PMCID: PMC8824395.
Yi, S., Yan, Y., Jin, M., Bhattacharya, S., Wang, Y., Wu, Y., Yang, L., Gine, E., Clot, G., Chen, L., Yu, Y., Zou, D., Wang, J., Phan, A.T., Cui, R., Li, F., Sun, Q., Zhai, Q., Wang, T., Yu, Z., Liu, L., Liu, W., Lyv, R., Sui, W., Huang, W., Xiong, W., Wang, H., Li, C., Xiao, Z., Hao, M., Wang, J., Cheng, T., Bea, S., Herrera, A.F., Danilov, A., Campo, E., Ngo, V.N., Qiu, L., & Wang, L. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest. 2022;132(3):e153283. PMID: 34882582; PMCID: PMC8803323.
Amador, C., Bouska, A., Wright, G., Weisenburger, D.D., Feldman, A.L., Greiner, T.C., Lone, W., Heavican, T., Smith, L., Pileri, S., Tabanelli, V., Ott, G., Rosenwald, A., Savage, K.J., Slack, G., Kim, W.S., Hyeh, Y., Li, Y., Dong, G., Song, J., Ondrejka, S., Cook, J.R., Barrionuevo, C., Lim, S.T., Ong, C.K., Chapman, J., Inghirami, G., Raess, P.W., Bhagavathi, S., Gould, C., Blombery, P., Jaffe, E., Morris, S.W., Rimsza, L.M., Vose, J.M., Staudt, L., Chan, W.C.*, & Iqbal, J.* Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. J Clin Oncol. 2022 Jul 15:JCO2102707. PMID: 35839444. *co-corresponding authors
Strati, P., Coleman, M., Champion, R., Ma, S., Patti, C., Levy, M.Y., Lossos, I.S., Geethakumari, P.R., Lam, S., Calvo, R., Higgins, K., & Budde, L.E. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol. 2022;199(1):76-85. PMID: 35861370.
Kambhampati, S., Saumoy, M., Schneider, Y., Serrao, S., Solaimani, P., Budde, L.E., Mei, M.G., Popplewell, L., Siddiqi, T., Zain, J., Forman, S.J., Kwak, L.W., Rosen, S.T., Danilov, A.V., Herrera, A.F., & Thiruvengadam, N. Cost Effectiveness of Second-Line Axicabtagene ciloleucel in Relapsed Refractory Diffuse Large B-cell Lymphoma. Blood. 2022 Aug 1:blood.2022016747. PMID: 35914220.
Kambhampati, S., Saumoy, M., Schneider, Y., Pak, S., Budde, L.E., Mei, M.G., Siddiqi, T., Popplewell, L., Wen, Y.P., Zain, J., Forman, S.J., Kwak, L.W., Rosen, S.T., Danilov, A.V., Herrera, A.F., & Thiruvengadam, N. Cost Effectiveness of Polatuzumab Vedotin Combined with Chemoimmunotherapy in Untreated Diffuse Large B-cell Lymphoma. Blood. 2022 Jun 14:blood.2022016624. doi: 10.1182/blood.2022016624. Epub ahead of print. PMID: 35700381.
Han, Z., Estephan, R.J., Wu, X., Su, C., Yuan, Y.C., Qin, H., Kil, S.H., Morales, C., Schmolze, D., Sanchez, J.F., Tian, L., Yu, J., Kortylewski, M., Rosen, S.T., & Querfeld, C. MicroRNA Regulation of T-Cell Exhaustion in Cutaneous T Cell Lymphoma. J Invest Dermatol. 2022 Mar;142(3 Pt A):603-612.e7. PMID: 34774537; PMCID: PMC8860868.
Herek, T.A., Bouska, A., Lone, W., Sharma, S., Amador, C., Heavican, T.B., Li, Y., Wei, Q., Jochum, D., Greiner, T.C., Smith, L., Pileri, S., Feldman, A.L., Rosenwald, A., Ott, G., Lim, S.T., Ong, C.K., Song, J., Jaffe, E.S., Wang, G.G., Staudt, L., Rimsza, L.M., Vose, J., d'Amore, F., Weisenburger, D.D., Chan, W.C.*, & Iqbal, J.* DNMT3A mutations define a unique biological and prognostic subgroup associated with cytotoxic T cells in PTCL-NOS. Blood. 2022;140(11):1278-1290. PMID: 35639959. *co-corresponding authors
Siddiqi, T., Soumerai, J.D., Dorritie, K.A., Stephens, D.M., Riedell, P.A., Arnason, J., Kipps, T.J., Gillenwater, H.H., Gong, L., Yang, L., Ogasawara, K., Thorpe, J., & Wierda, W.G. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022;139(12):1794-1806. PMID: 34699592.
Wang, X., Dong, Z., Awuah, D., Chang, W.C., Cheng, W.A., Vyas, V., Cha, S.C., Anderson, A.J., Zhang, T., Wang, Z., Szymura, S.J., Kuang, B.Z., Clark, M.C., Aldoss, I., Forman, S.J., Kwak, L.W., & Qin, H. CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute lymphoblastic leukemia. Leukemia. 2022;36(4):1015-1024. PMID: 35039637; PMCID: PMC8983465.